Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients

被引：12
|
作者：
Hifumi, Toru [1 ]
Isokawa, Shutaro [1 ]
Otani, Norio [1 ]
Ishimatsu, Shinichi [1 ]
机构：
[1] St Lukes Int Hosp, Dept Emergency & Crit Care Med, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan
来源：
CRITICAL CARE | 2020年 / 24卷 / 01期
关键词：
COVID-19; Adverse events; Nafamostat mesylate; Favipiravir;
D O I：
10.1186/s13054-020-03227-4
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Favipiravir-induced cutaneous adverse reactions in patients infected with COVID-19
    Punyaratabandhu, P.
    Vanitchpongphan, S.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2022, 47 (03) : 573 - 577
  • [22] Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19
    Zou, Jingrui
    Jing, Fuyuan
    PHARMACEUTICALS, 2022, 15 (12)
  • [23] Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database
    Kaur, Rimple Jeet
    Charan, Jaykaran
    Dutta, Siddhartha
    Sharma, Paras
    Bhardwaj, Pankaj
    Sharma, Praveen
    Lugova, Halyna
    Krishnapillai, Ambigga
    Islam, Salequl
    Haque, Mainul
    Misra, Sanjeev
    INFECTION AND DRUG RESISTANCE, 2020, 13 : 4427 - 4438
  • [24] Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
    Hoffmann, Markus
    Schroeder, Simon
    Kleine-Weber, Hannah
    Mueller, Marcel A.
    Drosten, Christian
    Poehlmann, Stefan
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (06)
  • [25] Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports
    Okajima, Masaki
    Takahashi, Yoshinori
    Kaji, Takaaki
    Ogawa, Naohiko
    Mouri, Hideyuki
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (21) : 5320 - 5325
  • [26] Fujifilm tests favipiravir as COVID-19 treatment
    Matsuoka, Katsumori
    CHEMICAL & ENGINEERING NEWS, 2020, 98 (15) : 11 - 11
  • [27] Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports
    Masaki Okajima
    Yoshinori Takahashi
    Takaaki Kaji
    Naohiko Ogawa
    Hideyuki Mouri
    World Journal of Clinical Cases, 2020, (21) : 5320 - 5325
  • [28] Favipiravir: A Possible Pharmaceutical Treatment for COVID-19
    Yanai, Hidekatsu
    JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2020, 10 (02) : 33 - 34
  • [29] Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients
    Fujii, Satoshi
    Ibe, Yuta
    Ishigo, Tomoyuki
    Inamura, Hirotoshi
    Kunimoto, Yusuke
    Fujiya, Yoshihiro
    Kuronuma, Koji
    Nakata, Hiromasa
    Fukudo, Masahide
    Takahashi, Satoshi
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2021, 27 (07) : 1051 - 1057
  • [30] Evaluation of the effect of favipiravir on patients with COVID-19
    Kamali, Alireza
    Sarmadian, Hossein
    Mahmoodiyeh, Behnam
    Valibeik, Shamim
    Farmani, Farzane
    Bashirgonbadi, Zahra
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2023, 12 (02) : 242 - 245
12345